Annual report: surveillance of adverse events following immunisation in Australia, 2004
DOI:
https://doi.org/10.33321/cdi.2005.29.23Keywords:
AEFI, adverse events, vaccines, surveillance, immunisation, vaccine safetyAbstract
Erratum: Annual report: surveillance of adverse events following immunisation in Australia, 2004
Table 1 incorrectly omitted rows for the Australian Capital Territory and New South Wales. The corrected table is reprinted in the attached Erratum document.
This report summarises Australian passive surveillance data on adverse events following immunisation (AEFI) for 2004 and describes reporting trends over the five years, 2000 to 2004. AEFIs are notified to the Adverse Drug Reactions Advisory Committee by state and territory health departments, hospitals, doctors and other health providers, vaccine manufactures, and the public. There were 975 AEFI records for vaccines received in 2004. This is an annual AEFI reporting rate of 4.8 per 100,000 population, the lowest since 2000, and a 33 per cent decrease compared with 2003 (1,460 records; 7.1 AEFI records per 100,000 population). Dose-based AEFI reporting rates in 2004 were 1.8 per 100,000 doses of influenza vaccine for adults aged =18 years and 11.8 per 100,000 doses of scheduled vaccines for children aged <7 years. The majority of records described non-serious events while nine per cent (n=88) described AEFIs defined as 'serious'. There were no reports of death related to immunisation. The most frequently reported individual AEFI was injection site reaction in children following a fifth dose of an acellular pertussis-containing vaccine (67 reports per 100,000 doses). The marked reduction in the AEFI reporting rate in 2004 coincided with the removal of the fourth dose of acellular pertussis vaccine, due at 18 months of age, from the vaccination schedule in September 2003 and fewer people receiving meningococcal C vaccine through the national catch-up vaccination program for those aged 1–19 years in 2004, compared with 2003. The consistently low reporting rate of serious AEFIs demonstrates the high level of safety of vaccines in Australia. Commun Dis Intell 2005;29:248–262.
Downloads
References
Mansoor O, Shin S, Maher C, and the Immunization Focus of WPRO. Immunization safety surveillance: guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. Manila: World Health Organization Regional Office for the Western Pacific; 1999.
Duclos P. A global perspective on vaccine safety. Vaccine 2004;22:2059–2063.
Chen RT, DeStefano F, Pless R, Mootrey G, Kramarz P, Hibbs B. Challenges and controversies in immunization safety. Infect Dis Clin North Am 2001;15:21–39.
National Health and Medical Research Council. The Australian Immunisation Handbook. 7th ed. Canberra: Australian Government Publishing Service; 2000.
National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. Canberra: Australian Government Publishing Service; 2003.
Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. Available from: http://www.who-umc.org Accessed on 27 July 2005.
Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Adverse events following immunisation: Australia 2000–2002. Commun Dis Intell 2003;27:307–323.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002–2003. Commun Dis Intell 2004;28:324–323
Lawrence G, Boyd I. Surveillance of adverse events following immunisation for children aged less than 7 years, 1 January to 30 June 2004. Commun Dis Intell 2004;28:490–492.
Australian Government Department of Health and Ageing. National meningococcal C vaccination program – information for immunisation providers. Available from: http://immunise.health.gov.au/meningoc_p.htm Accessed on 27 July 2005.
Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001. MMWR Surveill Summ 2003;52 SS-1:1–24. Erratum MMWR Morb Mortal Wkly Rep 2003;52:113.
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:109–117.
Bonhoeffer J, Gold MS, Heijbel H, Vermeer P, Blumberg D, Braun M, et al. Hypotonic-hyporesponsive episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine 2004:22;563–568.
The SAS system for Windows [computer program]. Version 8.02. Cary, NC: SAS Institute Inc.; 1999.
Australian Government Department of Health and Ageing. Additional reports – Childhood immunisation coverage. Commun Dis Intell 2005;29:328–330.
Australian Institute of Health and Welfare. 2004 Influenza Vaccine Survey: Summary Results. Canberra: Australian Institute of Health and Welfare; 2005.
Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004;23:287–294.
Rennels MB, Deloria MA, Pichichero ME, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000;105:e12.
Gold MS, Noonan S, Osbourn M, Precepa S, Kempe AE. Local reactions after the fourth dose of acellular pertussis vaccine in South Australia. Med J Aust 2003;179:191–194.
Report of the Committee on Safety of Medicines Expert Working Group on Meningococcal Group C Conjugate Vaccines. May 2002. Available from: http://www.mca.gov.uk/ourwork/monitorsafequalmed/safetymessages/mencwgreport.pdf Accessed on 27 July 2005.
Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000;284:1271–1279. E rratum JAMA 2000;284:3129.
Australian Government Department of Health and Ageing. National childhood pneumococcal vaccination program – information for immunisation providers. Available from: http://immunise.health.gov.au/universal/providers.htm Accessed on 27 July 2005.
Australian Government Department of Health and Ageing. National childhood varicella (chickenpox) vaccination program – information for immunisation providers. Available from: http://immunise.health.gov.au/varicella/providers.htm Accessed on 27 July 2005.
Australian Government Department of Health and Ageing. Press release: Minster for Health. Government to extend free vaccination program. Available from: http://www1.health.gov.au/internet/main/publishing.nsf/Content/health-mediarel-yr2005-ta-abb021.htm Accessed on 27 July 2005
Wise R, Iskander J, Pratt RD, Campbell S, Ball R, Pless RP, et al. Postlicensure safety surveillance for 7-valent pneumococcal conjugate vaccine. JAMA 2004;292:1702–1710.
Brotherton J, McIntyre P, Puech M, Wang H, Gidding H, Hull B, et al. Vaccine preventable diseases and vaccination coverage in Australia, 2001–2002. Commun Dis Intell 2004;28 Suppl 2:vii–S116.
Miller M, Roche P, Yohannes K, Spencer J, Bartlett M, Brotherton J, et al. Australia's notifiable diseases status, 2003: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2005;29:1–61.
Horby P, Gilmour R, Wang H, McIntyre P. Progress towards eliminating Hib in Australia: An evaluation of Haemophilus influenzae type b prevention in Australia, 1 July 1993 to 30 June 2000. Commun Dis Intell 2003;27:324–341.
Roche P, Krause V, Bartlett M, Coleman D, Cook H, Counahan M, et al. Invasive pneumococcal disease in Australia, 2003. Commun Dis Intell 2004;28:441–454.
The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2004. Commun Dis Intell 2005;29:149–158.
Downloads
Additional Files
Published
How to Cite
License
Copyright (c) 2005 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
